Company / Return on Equity (ROE)
Regeneron Pharmaceuticals Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
14.4%
FY2025
5-year range
14.4% / 31.9%
FY2021-FY2025
Trend
-4.1%
vs FY2024
Sector context
#31 of 190
Health Care
What the data says
Regeneron Pharmaceuticals's return on equity (roe) of 14.4% is higher than 84% of companies in the Health Care sector (FY2025). Return on Equity (ROE) has declined for 3 consecutive years, from 31.9% in FY2022 to 14.4% in FY2025.
Based on SEC 10-K filings.
14.4% in FY2025 with a 5-year CAGR of -13.5%. Top quartile in the Health Care sector.
Declined from 15.2% to 14.4% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -17.4pp
- 5-Year Change
- -13.5pp
- 10-Year Change
- -
Sector benchmark
+128.6% above sector average
Key checks
Key Insights
- Regeneron Pharmaceuticals's return on equity (roe) has declined for 3 consecutive years.
- In FY2025, return on equity (roe) decreased 4.1% year-over-year.
- Currently 64.7pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 14.4% | -4.1% |
| FY2024 | 15.0% | -1.2% |
| FY2023 | 15.2% | -52.2% |
| FY2022 | 31.9% | +67.0% |
| FY2021 | 19.1% | -31.6% |
| FY2020 | 27.9% | +46.3% |
| FY2019 | 19.1% | -31.6% |
| FY2018 | 27.9% | +43.1% |
| FY2017 | 19.5% | -3.1% |
| FY2016 | 20.1% | +15.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026